Treatment Strategies for High-Risk Localized and Locally Advanced and Oligometastatic Prostate Cancer

被引:9
作者
Makino, Tomoyuki [1 ,2 ]
Izumi, Kouji [1 ]
Iwamoto, Hiroaki [1 ]
Mizokami, Atsushi [1 ]
机构
[1] Kanazawa Univ, Dept Integrat Canc Therapy & Urol, Grad Sch Med Sci, 13-1 Takara Machi, Kanazawa, Ishikawa 9208640, Japan
[2] Ishikawa Prefectural Cent Hosp, Dept Urol, Kanazawa, Ishikawa 9208530, Japan
关键词
prostate cancer; locally advanced; oligometastasis; very high-risk; EXTERNAL-BEAM RADIOTHERAPY; ANDROGEN-DEPRIVATION THERAPY; DOSE-RATE BRACHYTHERAPY; LONG-TERM OUTCOMES; STEREOTACTIC BODY RADIOTHERAPY; MODULATED RADIATION-THERAPY; LYMPH-NODE DISSECTION; RADICAL PROSTATECTOMY; SURVIVAL OUTCOMES; MEN;
D O I
10.3390/cancers13174470
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The definitions of locally advanced and oligometastatic prostate cancer are ambiguous, and there are no standard treatments for these. Although multidisciplinary treatment combining systemic and local treatment may be effective, there are many unresolved issues such as the choice of local treatment, use of new endocrine agents and chemotherapy, and selection of optimal patients. The present article discusses the definitions, diagnoses, and treatment of very high-risk prostate cancer and oligometastatic prostate cancer. Despite the significant advances in the treatment of high-risk prostate cancer, patients with very high-risk features such as being locally advanced (clinical stage T3-4 or minimal nodal involvement), having a high Gleason pattern, or with oligometastasis may still have a poor prognosis despite aggressive treatment. Multidisciplinary treatment with both local and systemic therapies is thought to be effective, however, unfortunately, there is still no standard treatment. However, in recent years, local definitive therapy using a combination of radiotherapy and androgen deprivation is being supported by several randomized clinical trials. This study reviews the current literature with a focus on the definition of very high-risk prostate cancer, the role of modern imaging, and its treatment options.
引用
收藏
页数:16
相关论文
共 95 条
[1]  
Ahmed KA, 2012, FRONT ONCOL, V2, DOI [10.3389/fonc.2012.00215, 10.3389/fonc.2012.00172]
[2]   Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial [J].
Arcangeli, Giorgio ;
Saracino, Biancamaria ;
Arcangeli, Stefano ;
Gomellini, Sara ;
Petrongari, Maria Grazia ;
Sanguineti, Giuseppe ;
Strigari, Lidia .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (17) :1891-+
[3]   Salvage Stereotactic Body Radiotherapy for Patients With Limited Prostate Cancer Metastases: Deferring Androgen Deprivation Therapy [J].
Berkovic, Patrick ;
De Meerleer, Gert ;
Delrue, Louke ;
Lambert, Bieke ;
Fonteyne, Valerie ;
Lumen, Nicolaas ;
Decaestecker, Karel ;
Villeirs, Geert ;
Vuye, Philippe ;
Ost, Piet .
CLINICAL GENITOURINARY CANCER, 2013, 11 (01) :27-32
[4]   Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial [J].
Boeve, Liselotte M. S. ;
Hulshof, Maarten C. C. M. ;
Vis, Andre N. ;
Zwinderman, Aeilko H. ;
Twisk, Jos W. R. ;
Witjes, Wim P. J. ;
Delaere, Karl P. J. ;
van Moorselaar, R. Jeroen A. ;
Verhagen, Paul C. M. S. ;
van Andel, George .
EUROPEAN UROLOGY, 2019, 75 (03) :410-418
[5]   The role of radiotherapy in localised and locally advanced prostate cancer [J].
Bolla, Michel ;
Henry, Ann ;
Mason, Malcom ;
Wiegel, Thomas .
ASIAN JOURNAL OF UROLOGY, 2019, 6 (02) :153-161
[6]   External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study [J].
Bolla, Michel ;
Van Tienhoven, Geertjan ;
Warde, Padraig ;
Dubois, Jean Bernard ;
Mirimanoff, Rene-Olivier ;
Storme, Guy ;
Bernier, Jacques ;
Kuten, Abraham ;
Sternberg, Cora ;
Billiet, Ignace ;
Lopez Torecilla, Jose ;
Pfeffer, Raphael ;
Cutajar, Carmel Lino ;
Van der Kwast, Theodore ;
Collette, Laurence .
LANCET ONCOLOGY, 2010, 11 (11) :1066-1073
[7]   Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial [J].
Bowden, Patrick ;
See, Andrew W. ;
Frydenberg, Mark ;
Haxhimolla, Hodo ;
Costello, Anthony J. ;
Moon, Daniel ;
Ruljancich, Paul ;
Grummet, Jeremy ;
Crosthwaite, Alan ;
Pranavan, Ganes ;
Peters, Justin S. ;
So, Kevin ;
Gwini, Stella M. ;
McKenzie, Dean P. ;
Nolan, Skye ;
Smyth, Lloyd M. L. ;
Everitt, Craig .
INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (01) :161-168
[8]   Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial [J].
Brand, Douglas H. ;
Tree, Alison C. ;
Ostler, Peter ;
van der Voet, Hans ;
Loblaw, Andrew ;
Chu, William ;
Ford, Daniel ;
Tolan, Shaun ;
Jain, Suneil ;
Martin, Alexander ;
Staffurth, John ;
Camilleri, Philip ;
Kancherla, Kiran ;
Frew, John ;
Chan, Andrew ;
Dayes, Ian S. ;
Henderson, Daniel ;
Brown, Stephanie ;
Cruickshank, Clare ;
Burnett, Stephanie ;
Duffton, Aileen ;
Griffin, Clare ;
Hinder, Victoria ;
Morrison, Kirsty ;
Naismith, Olivia ;
Hall, Emma ;
van As, Nicholas .
LANCET ONCOLOGY, 2019, 20 (11) :1531-1543
[9]  
Brenner DJ, 2002, INT J RADIAT ONCOL, V52, P6
[10]   Fractionation and protraction for radiotherapy of prostate carcinoma [J].
Brenner, DJ ;
Hall, EJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 43 (05) :1095-1101